Other Stories

Moderna applies for emergency-use approval for its COVID-19 vaccine Updated: 2020-12-01 17:07:21 KST

U.S. pharmaceutical giant Moderna on Monday local time applied for emergency-use authorization to the U.S. Food and Drug Administration for its vaccine.
The company asked the FDA to review a data set proving that its vaccine is 94.1 percent effective at preventing COVID-19, and 100-percent effective in preventing severe cases of the virus.
The company's CEO said it is likely that approval will be granted between December 17th and Christmas saying that they feel very confident.

"But as you say, the most exciting news to me yesterday, when I learned the data, was the severe cases, because if we can prevent severe cases, it means reduced hospitalizations and no death, and that would be, of course, I believe, a game-changer in this pandemic."

Moderna is the second company to seek emergency-use authorization for its vaccine, after Pfizer applied on November 20th with a similar rate of efficacy.
With COVID-19 vaccines being developed at an astonishing pace, multinational investment bank Goldman Sachs forecasts that more than 70-percent of people in developed countries will be vaccinated by fall next year.
According to CNBC News, economists predict that the first doses of COVID-19 vaccines in the U.S. will go to those deemed to be high-risk, starting in mid-December.
They expect half the population of the U.S. and Canada to be vaccinated by April 2021,adding that it would lead to (quote) "significant public health benefits".
Then by October next year, it is expected that children under the age of 12 will start being inoculated once there are enough vaccines.
Meanwhile, it is forecasted that half the population of the U.K. will be vaccinated by March next year.
Bae Eun-ji, Arirang News.
KOGL : Korea Open Government License
본 저작물 중 본문에 해당하는 뉴스 스크립트(텍스트)는 공공누리 제1유형-출처표시 조건에 따라 이용할 수 있습니다.